Solid Biosciences Inc. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
Solid Biosciences Inc. (SLDB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.62 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- Solid Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $5.62M, a 78.57% increase year-over-year.
- Solid Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.15M, a 54.21% increase year-over-year.
- Solid Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.93M, a 31.15% increase year-over-year.
- Solid Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $3.15M, a 50.33% increase year-over-year.
- Solid Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $16.91M, a 60.79% increase from fiscal 2024.
- Solid Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $10.52M, a 37.95% increase from fiscal 2023.
- Solid Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $7.63M, a 1.17% increase from fiscal 2022.
- Solid Biosciences Inc. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $7.54M, a 43.64% decline from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.62M 10-Q · filed 2026-08-06 | $10.77M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $5.15M 10-Q · filed 2026-08-06 | |||
| 2025-12-31 | $16.91M 10-K · filed 2026-03-19 | |||
| 2025-09-30 | $3.93M 10-Q · filed 2025-11-03 | $7.07M derived: sum of 2 quarters · filed 2026-08-06 | $10.41M derived: sum of 3 quarters · filed 2026-08-06 | |
| 2025-06-30 | $3.15M 10-Q · filed 2026-08-06 | $6.49M derived: sum of 2 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $3.34M 10-Q · filed 2026-08-06 | |||
| 2024-12-31 | $10.52M 10-K · filed 2026-03-19 | |||
| 2024-09-30 | $3.00M 10-Q · filed 2025-11-03 | $5.09M derived: sum of 2 quarters · filed 2025-11-03 | $6.70M derived: sum of 3 quarters · filed 2025-11-03 | $8.64M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $2.09M 10-Q · filed 2025-11-03 | $3.70M derived: sum of 2 quarters · filed 2025-11-03 | $5.64M derived: sum of 3 quarters · filed 2025-11-03 | $7.27M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-03-31 | $1.61M 10-Q · filed 2025-11-03 | $3.55M derived: sum of 2 quarters · filed 2025-11-03 | $5.17M derived: sum of 3 quarters · filed 2025-11-03 | $7.12M derived: sum of 4 quarters · filed 2025-11-03 |
| 2023-12-31 | $1.94M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $3.56M derived: sum of 2 quarters · filed 2025-03-06 | $5.51M derived: sum of 3 quarters · filed 2025-03-06 | $7.63M 10-K · filed 2025-03-06 |
| 2023-09-30 | $1.63M 10-Q · filed 2024-11-06 | $3.57M derived: sum of 2 quarters · filed 2024-11-06 | $5.69M 10-Q · filed 2023-11-08 | $7.27M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-06-30 | $1.94M 10-Q · filed 2024-11-06 | $4.06M 10-Q · filed 2023-08-14 | $5.65M derived: sum of 3 quarters · filed 2024-11-06 | $7.17M derived: sum of 4 quarters · filed 2024-11-06 |
| 2023-03-31 | $2.12M 10-Q · filed 2024-11-06 | $3.71M derived: sum of 2 quarters · filed 2024-11-06 | $5.23M derived: sum of 3 quarters · filed 2024-11-06 | $7.04M derived: sum of 4 quarters · filed 2024-11-06 |
| 2022-12-31 | $1.59M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $3.11M derived: sum of 2 quarters · filed 2024-03-13 | $4.92M derived: sum of 3 quarters · filed 2024-03-13 | $7.54M 10-K · filed 2024-03-13 |
| 2022-09-30 | $1.52M 10-Q · filed 2023-11-08 | $3.34M derived: sum of 2 quarters · filed 2023-11-08 | $5.95M 10-Q · filed 2023-11-08 | $9.37M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-06-30 | $1.81M 10-Q · filed 2023-08-14 | $4.43M 10-Q · filed 2023-08-14 | $7.84M derived: sum of 3 quarters · filed 2024-03-13 | $11.26M derived: sum of 4 quarters · filed 2024-03-13 |
| 2022-03-31 | $2.61M 10-Q · filed 2023-05-11 | $6.03M derived: sum of 2 quarters · filed 2024-03-13 | $9.44M derived: sum of 3 quarters · filed 2024-03-13 | $13.08M derived: sum of 4 quarters · filed 2024-03-13 |
| 2021-12-31 | $3.42M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | $6.83M derived: sum of 2 quarters · filed 2024-03-13 | $10.47M derived: sum of 3 quarters · filed 2024-03-13 | $13.37M 10-K · filed 2024-03-13 |
| 2021-09-30 | $3.42M 10-Q · filed 2022-11-10 | $7.05M derived: sum of 2 quarters · filed 2022-11-10 | $9.96M 10-Q · filed 2022-11-10 | $12.48M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-06-30 | $3.63M 10-Q · filed 2022-08-11 | $6.54M 10-Q · filed 2022-08-11 | $9.06M derived: sum of 3 quarters · filed 2023-03-23 | $11.82M derived: sum of 4 quarters · filed 2023-03-23 |
| 2021-03-31 | $2.91M 10-Q · filed 2022-04-27 | $5.42M derived: sum of 2 quarters · filed 2023-03-23 | $8.19M derived: sum of 3 quarters · filed 2023-03-23 | $11.43M derived: sum of 4 quarters · filed 2023-03-23 |
| 2020-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-23 | $5.28M derived: sum of 2 quarters · filed 2023-03-23 | $8.53M derived: sum of 3 quarters · filed 2023-03-23 | $11.63M 10-K · filed 2023-03-23 |
| 2020-09-30 | $2.76M 10-Q · filed 2021-11-03 | $6.01M derived: sum of 2 quarters · filed 2021-11-03 | $9.11M 10-Q · filed 2021-11-03 | $12.52M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-06-30 | $3.24M 10-Q · filed 2021-08-16 | $6.35M 10-Q · filed 2021-08-16 | $9.75M derived: sum of 3 quarters · filed 2022-03-14 | $13.14M derived: sum of 4 quarters · filed 2022-03-14 |
| 2020-03-31 | $3.10M 10-Q · filed 2021-05-14 | $6.51M derived: sum of 2 quarters · filed 2022-03-14 | $9.90M derived: sum of 3 quarters · filed 2022-03-14 | $13.81M derived: sum of 4 quarters · filed 2022-03-14 |
| 2019-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-14 | $6.80M derived: sum of 2 quarters · filed 2022-03-14 | $10.71M derived: sum of 3 quarters · filed 2022-03-14 | $14.21M 10-K · filed 2022-03-14 |
| 2019-09-30 | $3.39M 10-Q · filed 2020-11-05 | $7.30M derived: sum of 2 quarters · filed 2020-11-05 | $10.80M 10-Q · filed 2020-11-05 | $12.83M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-06-30 | $3.91M 10-Q · filed 2020-08-06 | $7.41M 10-Q · filed 2020-08-06 | $9.44M derived: sum of 3 quarters · filed 2021-03-15 | $11.24M derived: sum of 4 quarters · filed 2021-03-15 |
| 2019-03-31 | $3.50M 10-Q · filed 2020-05-07 | $5.53M derived: sum of 2 quarters · filed 2021-03-15 | $7.33M derived: sum of 3 quarters · filed 2021-03-15 | $8.64M derived: sum of 4 quarters · filed 2021-03-15 |
| 2018-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $3.83M derived: sum of 2 quarters · filed 2021-03-15 | $5.14M derived: sum of 3 quarters · filed 2021-03-15 | $5.96M 10-K · filed 2021-03-15 |
| 2018-09-30 | $1.80M 10-Q · filed 2019-11-12 | $3.11M derived: sum of 2 quarters · filed 2019-11-12 | $3.92M 10-Q · filed 2019-11-12 | |
| 2018-06-30 | $1.31M 10-Q · filed 2019-08-14 | $2.13M 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | $819.00K 10-Q · filed 2019-05-13 | |||
| 2017-12-31 | $5.33M 10-K · filed 2020-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |